🧫 Our CYT-108 biopharmaceutical acts like a molecular predator, stalking and ensnaring the enzymes that chew up cartilage in OA. Here’s how it works.
Cytonics is on a mission to rid the world of osteoarthritis (OA) once and for all with our first-in-class biopharmaceutical, dubbed “CYT-108,” that attacks the disease at the molecular level. Unlike currently available palliative therapies which merely mask joint pain and inflammation (like NSAIDs and corticosteroids), CYT-108 is capable of addressing the root molecular cause of the disease, offering long-lasting relief through this “disease modification.” If approved by the FDA, CYT-108 will likely be the first and only disease-modifying therapy for OA, cracking open a $200-300B global market and forever changing the health and happiness of over 600M suffering people worldwide.
🧬 What Is CYT-108?
CYT-108 is a genetically engineered variant of the naturally occurring protein Alpha-2-Macroglobulin (A2M), which is found in the bloodstream and plays a role in clotting. We discovered that A2M can also serve as a defense mechanism against the enzymes, called proteases, that degrade cartilage in our joints, leading to OA. If concentrated and delivered into damaged joints, A2M can act as a protective shield, standing guard over the integrity of our joint cartilage.
🔬 How Does CYT-108 Work?
Imagine a molecular bear trap. That’s the essence of how CYT-108 operates. It has been engineered to enhance its efficacy, selectively binding to and neutralizing the catabolic proteases, much like a bear trap snapping shut on its target. This mechanism not only prevents cartilage degradation, but also reduces inflammation and shifts the balance towards cartilage tissue repair via the body’s natural regenerative mechanisms.
Here’s a more in-depth look into CYT-108 and how it functions on a molecular level to halt OA in its tracks.
We illustrate this dynamic process in mechanism of action video above. CYT-108, represented in blue/green, clamps down on the red protease, effectively disarming its cartilage-damaging activity. This visual encapsulates our therapeutic approach – a precisely targeted intervention that halts the progress of OA at the molecular level.
💊 Why is CYT-108 a powerful therapeutic for OA?
Current treatments for OA are symptomatic, merely addressing pain and inflammation without altering the course of the disease. CYT-108, however, is designed to be disease-modifying. By directly engaging the underlying cause of cartilage breakdown, CYT-108 is not just a band-aid; it’s potentially a cure.
Clinical studies have demonstrated that CYT-108 is up to 200% more effective than natural A2M. Our preclinical studies showcase CYT-108’s capacity to reduce cartilage damage significantly, heralding a new era where joint replacement surgeries could become a thing of the past.
🌟 Invest in the Future
Investing in Cytonics means joining a venture that stands on the precipice of a medical breakthrough. We are not merely offering a better treatment; we are offering a new understanding of joint health.
Ready to become a shareholder? Visit invest.cytonics.com.
This communication may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.
Leave a Reply